Please login to the form below

Not currently logged in
Email:
Password:

Forteo

This page shows the latest Forteo news and features for those working in and with pharma, biotech and healthcare.

Trulicity’s ascent lifts Lilly

Trulicity’s ascent lifts Lilly

These new medicines will be needed to offset continued decline in its older blockbuster medicines, Cialis and Forteo and Humulin, which all earned over $1bn in 2018, but will start to

Latest news

  • FDA rejects Amgen's osteoporosis hope romosozumab FDA rejects Amgen's osteoporosis hope romosozumab

    Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak, ... Forteo is heading for patent expiry, so Radius'

  • CHMP recommends Merck & Co's Lantus biosimilar CHMP recommends Merck & Co's Lantus biosimilar

    Also backs two biosimilar versions of Lilly’s osteoporosis therapy Forteo. EMA advisors have recommended Merck &Co's biosimilar version of Lantus, Sanofi's blockbuster basal insulin product, be approved. ... Forteo biosimilars. Meanwhile, the CHMP this

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo

  • Amgen and UCB's romosozumab hits goals in male osteoporosis Amgen and UCB's romosozumab hits goals in male osteoporosis

    Forteo is widely used in osteoporosis therapy and brought in sales of around $1.35bn last year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.

  • Amgen says romosozumab on track for 2016 filing Amgen says romosozumab on track for 2016 filing

    Amgen and UCB have previously reported data showing romosozumab was superior to Eli Lilly's parathyroid hormone-based Forteo (teriparatide), which requires daily dosing by injection. ... Forteo is widely used in osteoporosis therapy and brought in sales

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics